KLCM Advisors Inc. Has $5 Million Stock Position in Pfizer Inc. (NYSE:PFE)

KLCM Advisors Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 75.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 173,793 shares of the biopharmaceutical company’s stock after acquiring an additional 74,487 shares during the quarter. KLCM Advisors Inc.’s holdings in Pfizer were worth $5,004,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Moneta Group Investment Advisors LLC lifted its stake in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the period. Norges Bank acquired a new position in Pfizer in the fourth quarter valued at approximately $3,150,472,000. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares during the period. Morgan Stanley lifted its stake in Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after buying an additional 7,419,929 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Pfizer in the first quarter valued at approximately $311,238,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE:PFE traded down $0.22 during trading on Wednesday, reaching $25.69. The company’s stock had a trading volume of 28,885,313 shares, compared to its average volume of 33,467,946. The firm has a market cap of $145.47 billion, a price-to-earnings ratio of 71.36, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a 50 day moving average of $27.23 and a 200-day moving average of $28.79. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $41.33.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 EPS. Research analysts expect that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on PFE shares. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.